Fig. 9

Improvements in decreased neurogenesis and abnormal sub-localization of DCX-positive neurons in Hbegf cKO mice. a, Time schedule for drug treatments and sample preparation. b and c, Representative pictures of BrdU-staining following D-cycloserine or nefiracetam-treatments: (b) and quantitative comparisons: (c). n = 4 (all groups). **p < 0.01 versus Control-Saline, #p < 0.05 versus cKO-Saline. Values are the means ± s.e.m. d, Representative pictures of DCX-staining following D-cycloserine or nefiracetam-treatments. e, Effects of D-cycloserine and nefiracetam on mis-positioning of DCX-positive neurons in GCL and MOL of DG of cKO mice. Results were represented as % ratio of mis-positioned DCX-positive neurons (#3-5 layers) to total number of cells in each slice. *p < 0.05 (control-saline versus cKO-saline), ##p < 0.05 (cKO-saline versus cKO-nefiracetam). The numbers of animals used were 5, 5, 4, and 5, respectively. Values are the means ± s.e.m